The approval was based on data from the phase 3 ACTT-2 and COV-BARRIER studies.
Your search for supplemental oxygen returned 5 results
The studies evaluated routine clinical practice data from more than 800 hospitals in the US.
The sBLA is supported by data from 4 randomized, controlled studies that evaluated tocilizumab for the treatment of COVID-19 in more than 5500 hospitalized patients.
Actemra (tocilizumab) is an interleukin-6 receptor antagonist.
Kineret is an interleukin-1 receptor antagonist.